trial
as of 2026-07-01Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
NCTId NCT05658510
at a glance
Phase 3 · Completed
Enrollment 452 (actual)
Sponsored by BioXcel Therapeutics Inc
Primary completion 2025-08-15
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
452 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-11-21
Primary completion
2025-08-15
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Sponsors
BioXcel Therapeutics IncLead Sponsor
Worldwide Clinical TrialsCollaborator
Investigators
1
Matt Mandel, MDStudy Chair
Sites
24 total
Bellflower, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesLos Angeles, United StatesOceanside, United StatesOrange, United StatesRancho Cucamonga, United StatesRiverside, United StatesDenver, United StatesMiami, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
452
Phase
PHASE3
Primary Completion Date
2025-08-15
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
investigator
person